Jabil Completes Acquisition of Pharmaceutics International, Inc.
The transaction is expected to enhance Jabil’s development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com
Jabil, a St. Petersburg, Fla.-based company specializing in parenteral drug delivery and engineering, manufacturing, and supply chain solutions, announced it has successfully completed an acquisition of the contract development and manufacturing organization (CDMO) Pharmaceutics International, Inc. (Pii), which offers services in early stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing (1).
A Feb. 4, 2025 press release from Jabil said the acquisition, which includes a 360,000-square-foot footprint across four sites on a Hunt Valley, Md. campus, would enhance Jabil’s development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps (1).
“Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best solutions possible for patients around the world, we believe the addition of Pii’s capabilities, supported by over 300 team members, is a perfect fit for Jabil and our customers,” James O’Gorman, vice president, Pharmaceutical Solutions at Jabil, said in the press release. “The convergence of Jabil’s and Pii’s complementary capabilities will bolster Jabil's customer offering and support business growth potential as we enter the CDMO market.”
“This acquisition marks an exciting new chapter for Pii,” John Fowler, Pii president and CEO, said in the release. “We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and ultimately the patients we serve.”
Pii had announced, in November 2024, a $3.6 million investment into its prefilled syringe services, specifically boosting the company’s advanced labeling, automated visual inspection, and fill/finish technology (2). The branded syringe labeler intended as part of the investment was, as of that announcement, to be fully operational in the first or early second half of 2025, but the press release from Jabil did not specify the status of that project.
Pii’s state-of-the-art good manufacturing practice facilities contain, according to the press release, more than 70 manufacturing rooms—among them containment suites to handle high-potency compounds and hormones, dedicated suites for oral products, specifically soft gels, and an aseptic facility for injectables (1).
“As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly with a focus on quality and safety,” said Mike Mahaz, senior vice president of Global Business Units, Healthcare, at Jabil, said in the release. “Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain.”
In developments related to parenterals, in December 2024, Eli Lilly and Company (Lilly) announced plans to expand a manufacturing facility in Kenosha County, Wis., that it had purchased earlier in 2024 (3). The $3 billion investment in that site is intended to extend Lilly’s global parenteral product manufacturing network to meet growing demand for its diabetes and obesity therapies, as well as future pipeline medicines across therapeutic areas. Lilly said at the time that it expected to add 750 highly skilled jobs to a current, approximately 100-person workforce at the Kenosha County location.
Meanwhile, elsewhere in Maryland, Taiwan-based Bora Pharmaceuticals has expanded its North American footprint by purchasing, in June 2024, an 87,000-square-foot sterile manufacturing facility previously owned by Emergent BioSolutions, at a price of $30 million (4). Emergent, in turn, entered into a six-year commercial partnership with Hikma Pharmaceuticals, beginning in January 2025, for the sale of 8 mg naloxone hydrochloride nasal spray in the United States and Canada (5).
References
1. Jabil. Jabil Acquires Pharmaceutics International, Inc. Press Release. Feb. 4, 2025.
2. Pii Expands Prefilled Syringe Services with $3.6M Investment in Capacity and Technology Upgrades. Press Release. Nov. 19, 2024.
3. Eli Lilly and Company. Lilly Announces $3 Billion Expansion of its Recently Acquired Manufacturing Facility in Wisconsin. Press Release. Dec. 5, 2024.
4. Bora Pharmaceuticals. Bora Pharmaceuticals Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility. Press Release. June 20, 2024.
5. Hikma Pharmaceuticals. Hikma Announces Exclusive Commercial Partnership with Emergent BioSolutions for Kloxxado (naloxone HCl) Nasal Spray 8 mg. Press Release. Jan. 14, 2025.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
